A comprehensive view of Vertex Pharmaceuticals Inc.. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Government & Public Policy Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

Vertex reports Q1 GAAP net income up 17% from a year ago to US$762.0M, revenues up 22% year-over-year to US$2.1B, driven by Trikafta cystic fibrosis drug, with Health Canada approving drug for children 6-to-11 years of age; US sales up 9% year-over-year

FDA suspends early-stage clinic trial of Vertex’s VX-880 stem-cell therapy to potentially cure type 1 diabetes for ‘insufficient information’ to approve increased dose in tests; Vertex hopes continuing studies in Canada will assuage FDA concerns

Health Canada grants marketing authorization for Vertex’s oral Trikafta elexacaftor 50 mg/tezacaftor 25 mg/ivacaftor 37.5 mg and ivacaftor 75 mg to treat cystic fibrosis in kids 6-11 years old; CF affects about 500 kids in Canada, 83,000 people globally

Vertex announces positive results from two Phase 2 post-operative trials of VX-548 oral non-opioid pain drug in bunionectomy, abdominoplasty patients; company to start pivotal trials, development later this year

Ask us about our Government & Public Policy market view

Trending Chart

Interactive chart with headline count